News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
Health Canada Approves Meridian Bioscience, Inc.'s illumigene C. difficile Molecular Amplification Assay
October 1, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MassDevice -- Health Canada grants Meridian Bioscience Inc. an approved medical device license to begin selling the rapid illumigene C. difficile molecular test.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
MORE ON THIS TOPIC
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
·
3 min read
·
Annalee Armstrong
Podcast
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine
February 17, 2026
·
1 min read
·
Jef Akst
FDA
Moderna’s mRNA Vaccine Refusal Comes Amid Global Advanced Therapies Push
February 17, 2026
·
5 min read
·
Heather McKenzie
Complete response letters
FDA Rejects Disc’s Rare Blood Disease Drug Amid Reports of Prasad’s Skepticism
February 16, 2026
·
3 min read
·
Tristan Manalac
